BMC Ophthalmology · 2020 · 10 citations · 12 references
MedicineOncologyPharmacologyBreast OncologyMetastasisOcular OncologyCancer Stem CellsLimbal Stem Cell DeficiencyMalignant NeoplasmsMetastatic Breast CancerSystemic Therapy For Breast CancerSystemic Therapy For Ocular MalignanciesAdverse Ocular EffectsAntineoplastic Drug TherapyBreast Cancer Liver MetastasisLimbal Stem Cell Deficiency-associated LesionsLimbal Stem Cell InvolvementLiver Metastases TreatmentNeovascularizationPartial Limbal Stem Cell Deficiency
BACKGROUND: Paclitaxel (PTX) is an antineoplastic drug widely used in treatments for ovarian, breast, and small-cell lung cancer. Although ocular effects associated with PTX have been previously described, very few studies have specifically reported systemic PTX as a contributing factor for limbal stem cell deficiency (LSCD), which is characterized by the loss of stem cell and barrier function of the limbus leading to progressive pain and reduction in visual acuity. Described here is a unique case where a patient was diagnosed with LSCD secondary to PTX use for the treatment of breast cancer, at doses of PTX far lower than what is reported in current literature. CASE PRESENTATION: A 73-year-old woman with a previous diagnosis of breast cancer with liver metastasis presented with a complaint of increasing pain in the left eye more than the right, along with decreasing visual acuity in both eyes following 3 months of PTX therapy for recurrent liver metastases. Upon examination, best-corrected visual acuity was 20/100 in the right eye and counting fingers on the left. Peripheral neovascularization, stromal scarring, and features of limbal stem cell deficiency (LSCD) were noted on the right cornea. A central neurotrophic ulcer with thinning to 50% and 360 degrees of conjunctivalization were noted on the left. After the discontinuation PTX with doxorubicin as the substitute, there was no further progression of her LSCD, and stabilization of her ocular surface was achieved. CONCLUSION: Although chemotherapy induced LSCD is a relatively rare adverse event, it is essential for clinicians starting new chemotherapy agents to consider the potential ocular toxicities that may result in their use. Ophthalmology review is recommended for patients after starting PTX therapy to assess for signs of LSCD, particularly in patients where drug toxicity can be aggravated due to impaired hepatic function.
12
How Taxol/paclitaxel kills cancer cells
Beth A. Weaver · Molecular Biology of the Cell · 2014 · 1.6K citations
Medicine, Oncology, Pharmacology +13
Limbal epithelial stem cells of the cornea
Julie T. Daniels · StemBook · 2009 · 55 citations